LDLR and breast carcinoma: Effectively increasing the capacity to endocytose LDL, LDLR overexpression has been documented in pancreatic ductal adenocarcinoma (PDAC) [24,25], breast cancer [26,27], hepatocellular carcinoma (HCC) [28], lymphoma [29], lung adenocarcinoma [30,31], colorectal carcinoma [32,33], nasopharyngeal carcinoma [34], glioblastoma [35], leukemia [36] and renal cell carcinoma [37] (Table 1).